Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share acquisition event rather than general financial performance.
Material Changes
The material change reported is the acquisition of Ordinary Shares by Ms. C. Thomas, a PDMR, following the re-investment of dividends paid on October 1, 2015. The shares were acquired under the GSK 2009 Deferred Annual Bonus Plan Post-Tax at a price of 1294.81 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a routine disclosure of a director's share transaction.
Important Facts for Investors
- Transaction Type: Share acquisition via dividend re-investment under a deferred bonus plan.
- Individual Involved: Ms. C. Thomas (Person Discharging Managerial Responsibilities).
- Share Price: 1294.81 pence per share.
- Shares Acquired (Personal Contribution): 39.539 shares.
- Shares Acquired (GSK Matching Contribution): 39.748 shares.
- Notification Date: GSK was advised of the allocation on October 19, 2015.